Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for dvt
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on dvt or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on dvt and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Pharmacomechanical Catheter-Directed Thrombolysis for Deep-VeinThrombosis. The post-thrombotic syndrome frequently develops in patients with proximal deep-veinthrombosis despite treatment with anticoagulant therapy. Pharmacomechanical catheter-directed thrombolysis (hereafter "pharmacomechanical thrombolysis") rapidly removes thrombus and is hypothesized to reduce the risk of the post-thrombotic syndrome.We randomly assigned 692 patients with acute proximal deep-veinthrombosis to receive (...) not differ significantly between the treatment groups.Among patients with acute proximal deep-veinthrombosis, the addition of pharmacomechanical catheter-directed thrombolysis to anticoagulation did not result in a lower risk of the post-thrombotic syndrome but did result in a higher risk of major bleeding. (Funded by the National Heart, Lung, and Blood Institute and others; ATTRACT ClinicalTrials.gov number, NCT00790335 .).
Deepvenousthrombosis in elderly patients as a surgical emergency at King Abdulaziz University Hospital, Jeddah, Saudi Arabia Deepvenousthrombosis (DVT) is a condition that occurs frequently among surgical, as well as acutely ill hospitalized medical patients, and is responsible for significant morbidity and mortality in hospitalized patients. Risk factors include older age, surgery and immobilization (as with bed rest, orthopedic casts, and sitting on long flights.This study was conducted (...) to identify the frequency and factors associated with occurrence of DVT among elderly patients referred to King Abdulaziz University (KAU) Hospital, Jeddah, Kingdom of Saudi Arabia.The current study is a hospital based cross sectional study. The emergency, inpatients and outpatients' departments at KAU hospital were reviewed. We studied all the referred elderly subjects during the study period. All elderly patients (540) referred to or admitted to the hospital departments and who were clinically suspected
DeepVenousThrombosis among hypertensive patients in King Abdulaziz University (KAU) Hospital, Jeddah, Kingdom of Saudi Arabia Deepvenousthrombosis (DVT) is a frequent cardiovascular disorder. It is among the main causes of morbidity and mortality among hospitalized patients and, at the same time, can be easily avoided. Studies clarified that there are a variety of factors which can be significantly associated with the development of DVT in hospitalized patients.to identify frequency (...) and factors associated with occurrence of DVT among hypertensive patients referred to KAU hospital, Jeddah, Kingdom of Saudi Arabia.A cross-sectional hospital-based study was conducted from October 2016 to March, 2017. All hypertensive patients referred to or admitted to the hospital departments and who were suspected to have DVT and subjected to Doppler examination were included in the study. A questionnaire was designed to obtain data about DVT frequency among participants and factors associated
Deepvenousthrombosis among diabetic patients in King Abdulaziz University (KAU) Hospital, Jeddah, Kingdom of Saudi Arabia Deepvenousthrombosis (DVT) is a major cause of morbidity and mortality among hospitalized patients worldwide and, simultaneously, the most preventable. Studies revealed several risk factors of deepvenousthrombosis in hospitalized patients.to identify frequency and factors associated with occurrence of deepvenousthrombosis among diabetic patients referred to King (...) Abdulaziz University (KAU) Hospital, Jeddah, Kingdom of Saudi Arabia.This cross-sectional hospital-based study was conducted from June to December, 2016. All diabetic patients referred to the hospital departments and who were suspected to have deepvenousthrombosis (DVT) and subjected to Doppler examination were included in the study. A questionnaire was designed to obtain data about deepvenousthrombosis frequency among participants and factors associated with the development of deepvenous
Lixiana (edoxaban) - for the prevention of embolism in patients with nonvalvular atrial fibrillation OR treatment of deepveinthrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE. Lixiana (edoxaban) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Lixiana (edoxaban) Conclusion Lixiana (edoxaban) is the fourth Non-vitamin K Oral Anticoagulant (NOAC) in Denmark after Eliques (apixaban), Xarelto (rivaroxaban) and Pradaxa (...) (dabigatran). Lixiana is indicated for the prevention of embolism in patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors and treatment of deepveinthrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE. For either indication, Lixiana is not inferior to warfarin when it comes to preventing embolism and has a statistically significantly lower occurrence of major bleeding. The lower risk of bleeding is particularly evident in comparisons
Ultrasound-assisted versus conventional catheter-directed thrombolysis for acute iliofemoral deepveinthrombosis: 1-year follow-up data of a randomized-controlled trial Essentials Acute iliofemoral deepveinthrombosis can be treated with catheter-directed thrombolysis (CDT). We performed a randomized trial comparing conventional CDT versus ultrasound-assisted CDT (USAT). Clinical and duplex sonographic outcomes at 12 months were similar in the CDT and USAT groups. In both groups, incidence (...) of postthrombotic syndrome was very low with good quality of life.Background In patients with acute iliofemoral deepveinthrombosis (IFDVT), catheter-directed thrombolysis (CDT) aims to prevent the postthrombotic syndrome (PTS). Adding intravascular high-frequency, low-power ultrasound energy to CDT does not seem to improve the immediate thrombolysis results but its impact on clinical outcomes at 12 months is not known. Patients/Methods In this randomized-controlled trial, 48 patients (mean age 50 ± 21 years
of these diseases…. 1) List 8 DDx for DVT First off, DVT… This is a spectrum: isolated calf veinthrombosis ← to → limb threatening illiofemoral clot Here’s the anatomy you HAVE to know! (see picture) From the bottom up: Deepvenous system (is what we care about): Distal DVT = Calf veins : ant. + post. Tibial; peroneal vein. Proximal DVT = Thigh veins: popliteal, common femoral vein (formed from the “superficial” femoral vein and the deep femoral vein) NOTE that the superficial femoral vein – IS also known (...) CRACKCast E088 – Pulmonary Embolism & DeepVenousThrombosis CRACKCast E088 - Pulmonary Embolism & DeepVenousThrombosis - CanadiEM CRACKCast E088 – Pulmonary Embolism & DeepVenousThrombosis In , by Adam Thomas June 29, 2017 This episode of CRACKCast covers Rosen’s Chapter 88, DVT and PE. This episode covers the risk factors, diagnostic approach, treatment and management of PEs and DVTs. Shownotes – Rosen’s in Perspective This chapter is all about VTE – venous thromboembolism
, sex, and entry time. We compared incidence rates (IR) of pulmonary embolism (PE), deepveinthrombosis (DVT), and VTE between the 2 groups according to SS disease duration. We calculated HR, adjusting for confounders.Among 1175 incident pSS cases (mean age 56.7 yrs, 87.6% women), the IR of PE, DVT, and VTE were 3.9, 2.8, and 5.2 per 1000 person-years (PY), respectively; the corresponding rates in the comparison cohort were 0.9, 0.8, and 1.4 per 1000 PY. Compared with non-SS individuals (...) The Risk of DeepVenousThrombosis and Pulmonary Embolism in Primary Sjogren Syndrome: A General Population-based Study To estimate the future risk and time trends of venous thromboembolism (VTE) in individuals with newly diagnosed primary Sjögren syndrome (pSS) in the general population.Using a population database that includes all residents of British Columbia, Canada, we created a study cohort of all patients with incident SS and up to 10 controls from the general population matched for age
What Is the Utility of Thrombolytic Therapy for Acute DeepVenousThrombosis? TAKE-HOME MESSAGE Thrombolytic therapy increases the patency of veins and reduces the likelihood of post-thrombotic syndrome. However, this must be balanced against the increased risk of bleeding. What Is the Utility of Thrombolytic Therapy for Acute DeepVenousThrombosis? EBEM Commentators Michael Gottlieb, MD Thomas Alcorn, MD Department of Emergency Medicine Rush University Medical Center Chicago, IL Results (...) controlled trials that compared thrombolysis and anticoagulation versus anticoagulation alone for acute lower limb deepvenousthrombosis. The authors included only trials studying acute deepvenousthromboses. Studies assessing chronic or recurrent deepvenousthrombosis, as well as trials initiating treatment greater than 21 days after the onset of symptoms, were excluded. The CARDIOLOGY/SYSTEMATIC REVIEW SNAPSHOT Volume 70, no. 1 : July 2017 Annals of Emergency Medicine 41treatmentto1month
in patients with distal deepvenousthrombosis: systematic review. Thromb Res . 2014;134(6):1182-1185. [ ] 8. Spencer F, Kroll A, Lessard D, et al. Isolated calf deepveinthrombosis in the community setting: the Worcester Venous Thromboembolism study. J Thromb Thrombolysis . 2012;33(3):211-217. [ ] 9. Utter G, Dhillon T, Salcedo E, et al. Therapeutic Anticoagulation for Isolated Calf DeepVeinThrombosis. JAMA Surg . 2016;151(9):e161770. [ ] 10. De M, Wallaert J, Rossi A, Zbehlik A, Suckow B, Walsh D (...) . A meta-analysis of anticoagulation for calf deepvenousthrombosis. J Vasc Surg . 2012;56(1):228-37.e1; discussion 236-7. [ ] 11. Bernardi E, Camporese G, Büller H, et al. Serial 2-point ultrasonography plus D-dimer vs whole-leg color-coded Doppler ultrasonography for diagnosing suspected symptomatic deepveinthrombosis: a randomized controlled trial. JAMA . 2008;300(14):1653-1659. [ ] 12. Righini M, Galanaud J, Guenneguez H, et al. Anticoagulant therapy for symptomatic calf deepveinthrombosis
. Outcome: Propagation of clot to the popliteal veins or beyond, PE, bleeding, death, cost, patient satisfaction, quality of life. Search Strategy An advanced PubMed search was conducted using the strategy “calf AND (thrombosis OR DVT) AND anticoagulation” ( ) with 180 articles resulting. From these, the four most relevant articles were chosen. Articles Article 1: Schwarz T, Buschmann L, Beyer J, Halbritter K, Rastan A, Schellong S. Therapy of isolated calf muscle veinthrombosis: a randomized (...) , controlled study. J Vasc Surg. 2010 Nov;52(5):1246-50. Article 2: Lagerstedt CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-veinthrombosis. Lancet. 1985 Sep 7;2(8454):515-8. Article 3: Utter GH, Dhillon TS, Salcedo ES, Shouldice DJ, Reynolds CL, Humphries MD, White RH. Therapeutic Anticoagulation for Isolated Calf DeepVeinThrombosis. JAMA Surg. 2016 Jul 20:e161770. Article 4: Horner D, Hogg K, Body R, Nash MJ, Baglin T, Mackway-Jones
Aplastic anemia and risk of deepveinthrombosis and pulmonary embolism: A nationwide cohort study Deepveinthrombosis (DVT) and pulmonary embolism (PE) constitute venous thromboembolism (VTE), which is not fully known in aplastic anemia (AA). Therefore, we investigated the incidence and risk of VTE in AA patients.We conducted a nationwide cohort study to investigate the risk of DVT and PE in patients with AA. We identified patients with newly diagnosed AA as the AA cohort between 2000 (...) and 2010 from the National Health Insurance Research Database (NHIRD). The initial admission date for AA diagnosis was set as the index date. For each patient with AA, 4 patients without a history of AA, frequency matched by sex, age (every 5-y span), and year of index date, were the non-AA cohort. All patients were followed from the index date to the date of DVT or PE diagnosis, withdrawal from the NHIRD, or the end of 2011. Cox models were used to evaluate the risk of developing DVT and PE in the AA
DeepVeinThrombosis in Patients with Pulmonary Embolism: Prevalance, Clinical Significance and Outcome Deepvenousthrombosis (DVT) and pulmonary embolism (PE) are considered as similar disease entities representing different clinical manifestations. The objectives of this study were: 1) to determine the prevalence and outcome of DVT in patients with PE; 2) to identify additional risk factors for PE-related unfavorable outcome and 30-day all-cause mortality; and 3) to establish the clinical (...) importance of screening for concomitant DVT.From January 2013 to December 2015, a total of 141 patients with confirmed PE were evaluated. The prevalence and outcome of DVT in patients with PE was determined. Furthermore, the potential risk factors for PE-related unfavorable outcome and 30-day all-cause mortality were also analyzed.The prevalence of concomitant DVT was 45.4%. PE-related unfavorable outcome was observed in 21.9% of all concomitant DVT, with all-cause mortality of 21.9
Pharmacomechanical thrombectomy for iliofemoral deepveinthrombosis. Deepvenousthrombosis (DVT) occurs in approximately one in 1000 adults every year, and has an annual mortality of 14.6%. In particular, iliofemoral DVT can lead to recurrent thrombosis and post-thrombotic syndrome (PTS), a painful condition which can lead to chronic venous insufficiency, oedema, and ulceration. It causes significant disability, impaired quality of life, and economic burden. Early thrombus removal techniques (...) have been advocated in patients with an iliofemoral DVT in order to improve vein patency, prevent valvular dysfunction, and reduce future complications, such as post-thrombotic syndrome and venous ulceration. One such technique is pharmacomechanical thrombectomy, a combination of catheter-based thrombectomy and catheter-directed thrombolysis.To assess the effects of pharmacomechanical thrombectomy versus anticoagulation (alone or with compression stockings), mechanical thrombectomy, thrombolysis
decrease this complication.Background Upper-extremity venousthrombosis is associated with the use of peripherally inserted central catheters (PICCs). Few pediatric studies have focused on this issue. Objectives To determine the incidence and risk factors for PICC-related superficial veinthrombosis (SVT) and deepveinthrombosis (DVT) in children. Patients/methods An observational follow-up cohort study was conducted at a single hospital between June 2012 and June 2015. All patients receiving a PICC (...) Incidence and risk factors of superficial and deepveinthrombosis associated with peripherally inserted central catheters in children Essentials Pediatric studies on peripherally inserted central catheter (PICC)-related thrombosis are scarce. This study analyzes incidence and risk factors for PICC-related venousthrombosis in children. PICC-related thrombosis is a common, and nearly always, asymptomatic complication. Echo-guided insertion and a catheter to vein ratio < 0.33 may notably
Diagnosis and Treatment of Lower Extremity DeepVeinThrombosis: Korean Practice Guidelines Lower extremity deepveinthrombosis is a serious medical condition that can result in death or major disability due to pulmonary embolism or post-thrombotic syndrome. Appropriate diagnosis and treatment are required to improve symptoms and salvage the affected limb. Early thrombus clearance rapidly resolves symptoms related to venous obstruction, restores valve function and reduces the incidence of post (...) -thrombotic syndrome. Recently, endovascular treatment has been established as a standard method for early thrombus removal. However, there are a variety of views regarding the indications and procedures among medical institutions and operators. Therefore, we intend to provide evidence-based guidelines for diagnosis and treatment of lower extremity deepveinthrombosis by multidisciplinary consensus. These guidelines are the result of a close collaboration between interventional radiologists and vascular